3,554 results match your criteria Borderline Ovarian Cancer


Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls.

Authors:
Natalia Buza

Arch Pathol Lab Med 2019 Jan;143(1):47-64

From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

Context.—: Epithelial tumors of the ovary are one of the most frequently encountered gynecologic specimens in the frozen section laboratory. The preoperative diagnostic workup of an ovarian mass is typically limited to imaging studies and serum markers, both of which suffer from low sensitivity and specificity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0289-RADOI Listing
January 2019

EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors.

Curr Health Sci J 2018 Apr-Jun;44(2):129-134. Epub 2018 Mar 27.

Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania.

The epithelial growth factor receptor (EGFR) is involved in various stages of cancer growth such as tumor initiation, angiogenesis and metastasis, being an attractive target for oncogenic therapy. The present study aims to evaluate the EGFR expression in 54 cases of serous and mucinous ovarian borderline tumors and carcinomas. EGFR expression was present in more than half of the investigated tumors, more frequently in carcinomas than in borderline tumors, especially in the serous type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12865/CHSJ.44.02.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320459PMC

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.

Lancet Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium. Electronic address:

Background: Ovarian tumours are usually surgically removed because of the presumed risk of complications. Few large prospective studies on long-term follow-up of adnexal masses exist. We aimed to estimate the cumulative incidence of cyst complications and malignancy during the first 2 years of follow-up after adnexal masses have been classified as benign by use of ultrasonography. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183083
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30837-4DOI Listing
February 2019
2 Reads

TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer.

Cancer Manag Res 2019 17;11:839-855. Epub 2019 Jan 17.

Department of Obstetrics and Gynaecology, Shengjing Hospital Affiliated to China Medical University, Liaoning, China,

Background: Transmembrane protein with epidermal growth factor-like and two follistatin-like domains 1 (TMEFF1) has an anticarcinogenic effect in brain tumors. However, little is known about the role of TMEFF1 in epithelial ovarian cancer (EOC).

Materials And Methods: TMEFF1 expression in EOC was detected by immunohistochemistry; its relationship with clinical pathological parameters and its influence on prognosis were analyzed. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/tmeff1-overexpression-and-its-mech
Publisher Site
http://dx.doi.org/10.2147/CMAR.S186080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340504PMC
January 2019
6 Reads

Tumors of low malignant potential a single institution experience.

Int J Surg Case Rep 2019 Jan 19;55:41-46. Epub 2019 Jan 19.

Surgical Oncology Department, Institute Salah Azaiez de cancer, Tunis, Tunisia; Faculté de medicine, Tunis El Manar, Tunisia. Electronic address:

Background: The tumors of low malignant potential are an independent group of the ovarian epithelial tumors. They represents 10-20% of all ovarian epithelial tumors. Our aim through this study to determine how to treat this disease in the most suitable way. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351433PMC
January 2019
3 Reads

Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients

Asian Pac J Cancer Prev 2019 Jan 25;20(1):255-262. Epub 2019 Jan 25.

Institute of Chemical Biology and Fundamental Medicine, SB RAS, Novosibirsk, Russia.

Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Read More

View Article

Download full-text PDF

Source
http://journal.waocp.org/article_81713.html
Publisher Site
http://dx.doi.org/10.31557/APJCP.2019.20.1.255DOI Listing
January 2019
4 Reads

Assessing the landscape of ovarian serous borderline tumors.

Int J Gynecol Cancer 2019 Jan 18. Epub 2019 Jan 18.

Pathology Department, "IASO" Women's Hospital, Maroussi, Greece.

Aim: To compare distinct clinicopathological features between atypical proliferative serous tumors and non-invasive low-grade ovarian serous carcinomas.

Methods: Our study group comprised 203 cases of serous borderline tumors sub-classified as atypical proliferative serous tumors or as non-invasive low-grade serous carcinomas. All pathological features related to borderline tumors were re-evaluated by two gynecological pathologists. Read More

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2018-000086
Publisher Site
http://dx.doi.org/10.1136/ijgc-2018-000086DOI Listing
January 2019
16 Reads

Ovarian mucinous cystic tumor associated with sarcomatous mural nodule and benign Brenner tumor: A case report and literature review.

Medicine (Baltimore) 2019 Jan;98(3):e14066

Department of Obstetrics and Gynaecology, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, P.R. China.

Rationale: Ovarian mucinous tumor with malignant mural nodule is exceedingly rare. We report a case of ovarian mucinous cystic tumor associated with sarcomatous mural nodule and benign Brenner tumor and accompanied by nodular histiocytic aggregates in the greater omentum.

Patient Concerns: A 60-year-old postmenopausal woman was presented with a history of one month of lower abdominal discomfort, abdominal distension, nausea, and vomiting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014066DOI Listing
January 2019
7 Reads
5.723 Impact Factor

Rare metastatic patterns after malignant transformation of serous borderline tumor of the ovary.

J Surg Oncol 2019 Jan 15. Epub 2019 Jan 15.

Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.

Serous borderline tumors are rare, benign ovarian neoplasms that may recur and undergo malignant transformation to low-grade serous carcinomas (LGSCs). In this report, a 50-year-old female with a remote history of a serous borderline ovarian tumor experienced a recurrence of LGSC, presenting as a large solitary subcutaneous mass anterior to the sternum after a 33-year disease-free interval. The described case highlights the unpredictable nature of this disease and the importance of implementing lifelong surveillance strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25380DOI Listing
January 2019
2 Reads

High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.

Diagn Pathol 2019 Jan 12;14(1). Epub 2019 Jan 12.

Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Background: High-grade serous carcinoma, a representative high-grade ovarian carcinoma, is believed to be closely associated with a TP53 mutation. Recently, this category of ovarian carcinoma has gained increasing attention owing to the recognition of morphological varieties of TP53-mutated high-grade ovarian carcinoma. Herein, we report the case of a patient with high-grade serous carcinoma with mucinous differentiation. Read More

View Article

Download full-text PDF

Source
https://diagnosticpathology.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13000-019-0781-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330567PMC
January 2019
7 Reads

Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Clinical Practice at a Single Hospital in Korea.

Ann Lab Med 2019 05;39(3):252-262

Department of Obstetrics and Gynecology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Background: The risk of ovarian malignancy algorithm (ROMA) is used for assessing ovarian cancer risk in women with a pelvic mass. Its diagnostic accuracy is variable. We investigated whether the clinically acceptable minimal sensitivity of >80. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3343/alm.2019.39.3.252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340842PMC
May 2019
3 Reads

Borderline tumours of the ovary: Common practice in the Netherlands.

Gynecol Oncol Rep 2019 Feb 10;27:25-30. Epub 2018 Dec 10.

Isala Hospital, Department of Obstetrics and Gynaecology, Zwolle, the Netherlands.

Objectives: Discordance between frozen section diagnosis and the definite histopathological diagnosis and the fact that the frozen section result is not always unambiguous, may contribute to differences in clinical practice regarding perioperative treatment and follow-up of borderline ovarian tumours (BOTs) patients amongst gynaecologic oncologists, which may lead to over- and undertreatment. The aim of the study was to map the Dutch gynaecologists' preferred treatment and follow-up strategy in case of BOTs.

Methods: A questionnaire was sent to all Dutch gynaecologists involved in ovarian surgery with perioperative frozen section analysis, and the outcomes were assessed using descriptive statistics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2018.12.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297066PMC
February 2019
2 Reads

Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.

Int J Gynecol Pathol 2018 Dec 19. Epub 2018 Dec 19.

Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.) The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic (H.V., J.L.).

Mesonephric-like adenocarcinomas are rare neoplasms occurring in the uterine corpus and ovary which bear a close morphologic resemblance to cervical mesonephric adenocarcinomas. They also have a similar immunophenotype and harbor similar molecular abnormalities to mesonephric adenocarcinomas and it is debated whether they are truly of mesonephric origin or represent Mullerian neoplasms closely mimicking mesonephric adenocarcinomas. We report an unusual case with bilateral ovarian serous borderline tumors and extraovarian low-grade serous carcinoma (invasive implants). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000573DOI Listing
December 2018
1 Read

Rapidly growing juvenile granulosa cell tumor of the ovary arising in adult: a case report and review of the literature.

J Ovarian Res 2018 Dec 14;11(1):100. Epub 2018 Dec 14.

Department of Radiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan.

Background: Ovarian granulosa cell tumors (GCTs) are divided into adult GCT (AGCT) and juvenile GCT (JGCT). The AGCT is more common type, conversely, less than 5% of tumors are the JGCT and occur in mainly premenarchal girls and in women younger than 30 years. Although JGCT have different histologic features compared to AGCT, the two types have similar imaging features because they have similar gross appearance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-018-0474-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293549PMC
December 2018
2 Reads

Risk of cancer after assisted reproduction: a review of the available evidences and guidance to fertility counselors.

Eur Rev Med Pharmacol Sci 2018 Nov;22(22):8042-8059

Gynecological Oncology, National Cancer Institute, Aviano, Italy.

Objective: Infertile women requiring ovarian stimulation and assisted reproduction techniques (ART) are faced with difficult issues. The fear that using hormones could increase their risk of cancer is the most significant. One of the main challenges for assessing cancer risk after ART is the difficulty to separate it from the underlying condition of infertility per se. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201811_16434DOI Listing
November 2018
1 Read

The value of MR-detectable ipsilateral ovaries in characterizing the origin and malignancy of an adnexal tumors.

Eur J Radiol 2018 Dec 26;109:62-67. Epub 2018 Oct 26.

Department of Radiology, Jinshan Hospital, Fudan University, 1508 Longhang Road, Shanghai 201508, China. Electronic address:

Objective: To investigate the magnetic resonance (MR) imaging morphological relationship between adnexal tumors and the ipsilateral ovaries to characterize the origin and malignancy of tumors.

Material And Methods: Clinical and MR imaging data of 496 adnexal tumors confirmed by histology (ovary tumors, n = 400, non-ovarian tumors, n = 96; benign tumors, n = 183, borderline tumors, n = 120, and malignant tumors, n = 193) were retrospectively analyzed. The presence and shape of the ipsilateral ovaries within the context of adnexal tumors of different origins, malignancies and configurations were evaluated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0720048X183037
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2018.10.027DOI Listing
December 2018
8 Reads

ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer.

J Cancer 2018 21;9(23):4334-4340. Epub 2018 Oct 21.

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Evidence for an association between ABO blood type and epithelial ovarian cancer (EOC) survival has so far been limited and conflictive. This study applied a retrospective cohort and included 627 EOC patients diagnosed at Shengjing Hospital of China Medical University between 2011 and 2015. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) between the ABO blood type and progression-free survival (PFS) and overall survival (OS) of EOC patients were assessed using multivariable Cox proportional regression models. Read More

View Article

Download full-text PDF

Source
http://www.jcancer.org/v09p4334.htm
Publisher Site
http://dx.doi.org/10.7150/jca.27734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277646PMC
October 2018
10 Reads

Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.

Oncol Rep 2019 Feb 27;41(2):917-927. Epub 2018 Nov 27.

Department of Gynaecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.

Metastasis is the most common cause of death in ovarian cancer patients but remains largely untreated. Epithelial‑mesenchymal transition (EMT) is critical for the conversion of early‑stage ovarian tumors into metastatic malignancies. Thus, investigating the signaling pathways promoting EMT may identify potential targets for the treatment of metastatic ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6888DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313075PMC
February 2019
4 Reads
2.191 Impact Factor

Ovarian Endometrioid Carcinoma Misdiagnosed as Mucinous Carcinoma: An Underrecognized Problem.

Int J Gynecol Pathol 2018 Nov 21. Epub 2018 Nov 21.

Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada (R.W., M.K.) Hollings Cancer Center and Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, South Carolina (L.E.K.).

Primary mucinous carcinoma of the ovary is uncommon, and while numerous studies have focused on improving our ability to distinguish these tumors from gastrointestinal metastases, recent data suggest that up to one fifth are still misdiagnosed with a previously underrecognized culprit: endometrioid carcinoma. Using an index case of an ovarian endometrioid carcinoma with mucinous differentiation masquerading as a mucinous carcinoma, we sought to identify the most efficient biomarker combination that could distinguish these 2 histotypes. Eight immunohistochemical markers were assessed on tissue microarrays from 183 endometrioid carcinomas, 77 mucinous carcinomas, and 72 mucinous borderline tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000564DOI Listing
November 2018
15 Reads

MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.

Proteomics Clin Appl 2019 Jan 14;13(1):e1700181. Epub 2018 Dec 14.

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Purpose: Precise histological classification of epithelial ovarian cancer (EOC) has immanent diagnostic and therapeutic consequences, but remains challenging in histological routine. The aim of this pilot study is to examine the potential of matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry in combination with machine learning methods to classify EOC histological subtypes from tissue microarray.

Experimental Design: Formalin-fixed-paraffin-embedded tissue of 20 patients with ovarian clear-cell, 14 low-grade serous, 19 high-grade serous ovarian carcinomas, and 14 serous borderline tumors are analyzed using MALDI-Imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prca.201700181DOI Listing
January 2019
6 Reads

Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours.

BMC Cancer 2018 Nov 23;18(1):1160. Epub 2018 Nov 23.

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, People's Republic of China.

Background: Because of the rarity of endometrioid borderline ovarian tumours (EBOTs), there is a paucity of data concerning the natural history and prognosis of this condition. Thus, the objective of our study was to establish the feasibility of fertility preservation in young women with EBOTs, as well as their oncological and reproductive outcomes.

Methods: Consecutive patients with EBOTs, treated at a tertiary referral centre during a span of 22 years, were retrospectively analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-5091-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251198PMC
November 2018
2 Reads

Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell.

Onco Targets Ther 2018 2;11:7745-7761. Epub 2018 Nov 2.

Department of Gynaecology and Obstetrics, Shengjing Hospital Affiliated to China Medical University, Heping District, Shenyang 110004, Liaoning, China,

Aim: The aim of this study was to explore the expression of peroxiredoxin1 (PRDX1) in epithelial ovarian cancer, analyze the relationship between PRDX1 and clinicopathologic parameters of patients with ovarian cancer, including their prognosis, and describe changes and the mechanisms involved in malignant biologic behavior of ovarian cancer cells when PRDX1 expression is inhibited.

Methods: The expression of PRDX1 was detected immunohistochemically in 15 samples of normal ovarian tissue, 21 benign, 11 borderline, and 101 malignant epithelial ovarian tumors. Changes in ovarian cancer cell proliferation, invasion, and metastasis before and after inhibiting PRDX1 expression were assessed by cell function assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S175009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223347PMC
November 2018
10 Reads

The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors.

BMC Cancer 2018 Nov 21;18(1):1147. Epub 2018 Nov 21.

Department of Gynecological Oncology, Zhejiang Cancer Hospital, 1 Banshan East Road, Hangzhou, 310022, Zhejiang Province, China.

Background: Fertility sparing surgery has been extensively performed among patients with borderline ovarian tumors due to their age and favorable prognosis. Nevertheless, the prognosis and obstetric outcomes in these patients remain uncertain. Thus, the current study was carried out to evaluate the oncological safety and fertility benefits of different fertility sparing surgery subtypes and various clinicopathological parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4932-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249857PMC
November 2018
7 Reads

Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.

Curr Probl Cancer 2018 Nov 6. Epub 2018 Nov 6.

Department of Pathology, Faculty of Medicine, Taibah University, Almadinah Almunawwarah, Saudi Arabia; Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. Electronic address:

Alteration of expression of the tumor suppressor gene BRCA-1 has been widely studied in breast and ovarian carcinoma. However, pattern of this alteration in the benign-borderline-carcinoma sequence in serous and mucinous ovarian neoplasms have not yet fully described. Tissue sections from 214 formalin-fixed paraffin-embedded ovarian specimens were stained immunohistochemically with BRCA-1 antibody. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01470272183027
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2018.10.003DOI Listing
November 2018
11 Reads

Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.

Diagn Pathol 2018 Nov 14;13(1):87. Epub 2018 Nov 14.

Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 20032, China.

Background: Regulated in development and DNA damage response (REDD1), a gene responding to hypoxia or multiple DNA damage events, was recently implicated in cancer development and progression. Previously, in vivo and in vitro experiments indicated that REDD1 functions as an oncogene in ovarian cancer cells. However, the role of REDD1 in cancer cell migration and invasion and in clinical significance of prognostic values is not examined in detail. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-018-0754-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236897PMC
November 2018
16 Reads

Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.

J Obstet Gynaecol Res 2019 Feb 13;45(2):289-298. Epub 2018 Nov 13.

Department of Obstetrics and Gynecology, Niigata University Medical School, Niigata, Japan.

Aim: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2015 and the Annual Treatment Report for 2010 on the outcomes of patients who started treatment in 2010.

Methods: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment was initiated in 2015 were analyzed retrospectively. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jog.13863
Publisher Site
http://dx.doi.org/10.1111/jog.13863DOI Listing
February 2019
11 Reads

Synchronous endometrial and ovarian cancer in Lynch syndrome with a germline mutation: A case report.

Mol Clin Oncol 2018 Nov 17;9(5):479-484. Epub 2018 Sep 17.

Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Synchronous endometrial and ovarian cancer (SEOC) is a rare entity among gynecological cancers, which exhibits endometrioid histology in its early stages and generally has a good prognosis. However, diagnosis is difficult and recent reports have demonstrated that most clinically diagnosed cases of SEOC have clonally related cancers, indicating metastatic cancer. The association of SEOC with Lynch syndrome is also not clearly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2018.1723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201051PMC
November 2018
2 Reads

Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer.

Anticancer Res 2018 Nov;38(11):6507-6511

Department of Obstetrics and Gynecology, Division of Gynecology, LKH University Hospital Graz, Graz, Austria.

Background: Two studies have found primary ovarian carcinomas in stage I disease to be larger than those in stage III. Thus, these stages may represent different tumor entities.

Materials And Methods: The clinical data from 553 patients operated on between 1985 and 2012 for epithelial ovarian cancer were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13015DOI Listing
November 2018
3 Reads

Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.

Ginekol Pol 2018 ;89(10):568-572

Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Poland.

Introduction: Ovarian cancer (OC) diagnosis remains a clinical challenge due to lack of early symptoms and insufficient accuracy of the available diagnostic methods. The purpose of this study was to determine whether osteopontin could be useful in differential diagnosis of ovarian tumors.

Material And Methods: Serum samples from 92 patients qualified for surgical treatment due to ovarian mass were divided into 2 groups according to the histopathological result: OC including borderline ovarian tumors (n = 39) and benign ovarian tumors (BOTs) (n = 53). Read More

View Article

Download full-text PDF

Source
https://journals.viamedica.pl/ginekologia_polska/article/vie
Publisher Site
http://dx.doi.org/10.5603/GP.a2018.0097DOI Listing
January 2018
11 Reads

Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution.

J Obstet Gynaecol 2019 Feb 29;39(2):253-258. Epub 2018 Oct 29.

a The Faculty of Medicine , Istanbul University , İstanbul , Turkey.

This study was conducted to determine the demographic and clinicopathologic characteristics and evaluate the prognostic value of various factors, such as the extensiveness of surgery, related to the tumour itself and the clinical features in the recurrence of borderline ovarian tumours (BOT). We retrospectively evaluated the data of 103 patients with a borderline ovarian tumours treated at our institution between the years 2000 and 2012. The median age was 37 (16-79) years and the majority of the patients were premenopausal (76. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/01443615.2018.1
Publisher Site
http://dx.doi.org/10.1080/01443615.2018.1499076DOI Listing
February 2019
11 Reads

Borderline Ovarian Tumors: Fifteen Years' Experience at a Scottish Tertiary Cancer Center.

Int J Gynecol Cancer 2018 Nov;28(9):1683-1691

Department of Gynaecology Oncology, Simpson Centre for Reproductive Health, Royal Infirmary Edinburgh, Edinburgh, Scotland.

Objectives: Since the recognition of borderline ovarian tumors (BOTs) in the 1970s, the management of this subset of epithelial ovarian tumors has presented a challenge to clinicians. The majority present at an early stage, but their diagnosis is often only made following surgery, hence the heterogeneity of surgical management. Borderline ovarian tumors are morphologically diverse, and their behavior is subsequently also heterogeneous. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001364DOI Listing
November 2018
14 Reads

Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years.

Int J Gynecol Cancer 2018 Nov;28(9):1643-1649

Departments of Gynecological Oncology and.

Objective: This study aimed to evaluate the clinicopathologic features of mucinous borderline ovarian tumors (MBOTs), with an emphasis on the risk factors for recurrence.

Methods: Data of 76 patients with MBOT diagnosed and treated between 2000 and 2007 at a single institution were analyzed in this retrospective study. The clinicopathologic features of different tumor subgroups were analyzed, including pathology, surgical methodology, recurrence, and overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001362DOI Listing
November 2018
17 Reads

Four cases of endometrioid borderline ovarian tumour: case reports and literature review.

BJR Case Rep 2018 21;4(1):20170062. Epub 2017 Oct 21.

Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Endometrioid borderline tumours (EBTs) of the ovary are uncommon tumours of low malignant potential. They consist of atypical endometrioid cells lacking destructive stromal invasion. As the prognosis of EBT is excellent, excessive treatment should be avoided and preoperative diagnosis is important. Read More

View Article

Download full-text PDF

Source
http://www.birpublications.org/doi/10.1259/bjrcr.20170062
Publisher Site
http://dx.doi.org/10.1259/bjrcr.20170062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159154PMC
October 2017
15 Reads

Role of proton MR spectroscopy in the differentiation of borderline from malignant epithelial ovarian tumors: A preliminary study.

J Magn Reson Imaging 2018 Oct 24. Epub 2018 Oct 24.

Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

Background: Due to the overlapping imaging appearances between borderline and malignant epithelial ovarian tumors (EOTs), borderline EOTs often represent a diagnostic challenge on conventional MRI. Proton magnetic resonance spectroscopy ( H-MRS) might have potential to differentiate borderline from malignant tumors.

Purpose: To investigate the ability of H-MRS to differentiate borderline from malignant EOTs. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jmri.26541
Publisher Site
http://dx.doi.org/10.1002/jmri.26541DOI Listing
October 2018
10 Reads

Comparison of Laparoscopic and Open Surgery for Patients With Borderline Ovarian Tumors.

Int J Gynecol Cancer 2018 Nov;28(9):1657-1663

Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Objectives: The aim of this study was to compare surgical and oncologic outcomes of open and laparoscopic surgery in patients with borderline ovarian tumors (BOTs).

Materials And Methods: This study included patients with BOTs who underwent open (n = 433) or laparoscopic (n = 210) surgery between 1990 and 2015. Surgical outcomes, perioperative morbidity, and disease-free survival and overall survival were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001358DOI Listing
November 2018
18 Reads

The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.

Minerva Ginecol 2019 Feb 11;71(1):36-43. Epub 2018 Oct 11.

Department of Obstetrics and Gynecology, Campus Bio-Medico University, Rome, Italy.

Introduction: The serum levels of glycoprotein human epididymis protein 4 (HE4) have been widely investigated in patients with ovarian cancer as a tumor marker to differentiate benign gynecological tumors from ovarian cancers (OC). A few studies demonstrated the promising role of HE4 in endometrial cancer (EC) too. The aim of this review is to provide an outline of published studies investigating HE4 in the diagnosis of gynecologic malignancies, focusing on its role in OC and EC. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R09Y9999N00A181
Publisher Site
http://dx.doi.org/10.23736/S0026-4784.18.04328-9DOI Listing
February 2019
20 Reads

Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer.

Medicine (Baltimore) 2018 Oct;97(41):e12364

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi.

The sensitivity of tumor cells to chemotherapy drugs may become attenuated accounts for various reasons. Reduced drug sensitivity may cause the failure of chemotherapy and affect the prognosis of patients with cancer. This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203479PMC
October 2018
14 Reads
5.723 Impact Factor

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

BMC Cancer 2018 Oct 11;18(1):970. Epub 2018 Oct 11.

Department of Obstetrics & Gynecology, University of Southern California, 1450 Biggy Street, Los Angeles, CA, 90033, USA.

Background: Prior small studies have shown increased expression of sperm protein 17 (Sp17) in epithelial ovarian cancer (EOC) tissue and suggest Sp17 as a potential biomarker for EOC. However, how Sp17 expression varies with histology, grade, and stage of EOC and its expression in other ovarian neoplasms has not been defined. It is unknown whether patients with EOC have elevated serum Sp17 levels or if Sp17 expression is associated with survival outcomes. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-4880-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182788PMC
October 2018
3 Reads

Prospective Validation of a Standardized Ultrasonography-Based Ovarian Cancer Risk Assessment System.

Obstet Gynecol 2018 Nov;132(5):1101-1111

Division of Gynecologic Oncology, Regional Women's Health, and Regional Imaging, The Permanente Medical Group, Walnut Creek, and the Division of Research, Kaiser Permanente Northern California, Oakland, California.

Objective: To evaluate the performance of a system that standardizes ovarian cancer risk assessment and reporting on ultrasonography.

Methods: We conducted a prospective community-based cohort study of average-risk women undergoing ultrasonography in 2016 using a reporting system that requires adnexal masses to be categorized as 1, 2, 3, or X based on standardized ultrasound criteria including size, presence of solid components, and vascularity assessed by Doppler. With a median follow-up of 18 months, the risk of ovarian cancer or borderline tumor diagnosis for each category was determined. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006250-900000000-9790
Publisher Site
http://dx.doi.org/10.1097/AOG.0000000000002939DOI Listing
November 2018
3 Reads

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.

Br J Cancer 2018 Oct 8;119(7):847-854. Epub 2018 Oct 8.

Zora Biosciences Oy, Espoo, Finland.

Background: Previous results obtained from serum samples of late-stage, high-grade serous ovarian carcinoma patients showed large alterations in lipid metabolism. To validate and extend the results, we studied lipidomic changes in early-stage ovarian tumours. In addition to serous ovarian cancer, we investigated whether these changes occur in mucinous and endometrioid histological subtypes as well. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0270-z
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0270-zDOI Listing
October 2018
3 Reads

Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.

Oncol Rep 2018 Dec 24;40(6):3725-3733. Epub 2018 Sep 24.

Yunnan Engineering Technology Center of Diagnosis and Treatment of Digestive Diseases, Kunming, Yunnan 650032, P.R. China.

Alanine serine cysteine‑preferring transporter 2 (ASCT2; also known as SLC1A5) is an important glutamine transporter, and it serves a crucial role in tumor growth and progression. ASCT2 is highly expressed in numerous types of cancer, but the pathological significance of its expression in epithelial ovarian cancer (EOC) remains unclear. The mechanistic target of rapamycin (mTOR) level is hyperelevated in a number of tumor types, including ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6729DOI Listing
December 2018
4 Reads

Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark.

Gynecol Oncol 2018 12 21;151(3):513-518. Epub 2018 Sep 21.

Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark; Department of Gynecology, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. Electronic address:

Objective: Few studies have examined ovarian borderline tumor (BOT) risk associated with analgesics, and with inconclusive findings. The aim was to examine serous borderline tumor (SBT) or mucinous borderline tumor (MBT) risk associated with use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs).

Methods: We identified all women with SBTs or MBTs in the Danish Pathology Data Bank, 1997-2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.09.022DOI Listing
December 2018
2 Reads

A study detection of the ROS1 gene fusion by FISH and ROS1 protein expression by IHC methods in patients with ovarian malignant or borderline serous tumors.

Pathol Res Pract 2018 Nov 18;214(11):1868-1872. Epub 2018 Sep 18.

Department of Gynecologic Oncology, Akdeniz University School of Medicine, Antalya, Turkey. Electronic address:

Objective: ROS1 is an orphan receptor protein tyrosine kinase which is supposed to undergo genetic rearrangement in carcinogenesis. In the current study, we aimed to investigate the frequency and clinicopathologic features associated with ROS1 gene fusion and ROS1 protein expression in patients with ovarian serous carcinoma or serous borderline tumors.

Materials And Methods: Tissue samples of 102 patients with high or low grade serous carcinoma and borderline serous tumors were selected randomly from the archives of Department of Gyneco-pathology, and analyzed for ROS1 gene expression. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03440338183083
Publisher Site
http://dx.doi.org/10.1016/j.prp.2018.09.016DOI Listing
November 2018
17 Reads

Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors.

J Pathol 2018 Dec 19;246(4):459-469. Epub 2018 Oct 19.

Department of internal medicine specialties, Facutly of Medicine, Université de Genève, Geneva, Switzerland.

Mucinous ovarian tumors (MOTs) morphologically and epidemiologically resemble mucinous cystic neoplasms (MCNs) of the pancreas, sharing a similar stroma and both occurring disproportionately among young females. Additionally, MOTs and MCNs share similar clinical characteristics and immunohistochemical phenotypes. Exome sequencing has revealed frequent recurrent mutations in KRAS and RNF43 in both MOTs and MCNs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240919PMC
December 2018
18 Reads
7.430 Impact Factor

mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea.

J Gynecol Oncol 2018 Nov;29(6):e90

Department of Laboratory Medicine, Keimyung University School of Medicine, Daegu, Korea.

Objective: We performed small-scale mutation and large genomic rearrangement (LGR) analysis of in ovarian cancer patients to determine the prevalence and the characteristics of the mutations.

Methods: All ovarian cancer patients who visited a single institution between September 2015 and April 2017 were included. Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and long-range polymerase chain reaction (PCR) were performed to comprehensively study . Read More

View Article

Download full-text PDF

Source
https://ejgo.org/DOIx.php?id=10.3802/jgo.2018.29.e90
Publisher Site
http://dx.doi.org/10.3802/jgo.2018.29.e90DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189434PMC
November 2018
10 Reads

A Preoperative Scoring System for Adnexal Mass in Children and Adolescents to Preserve Their Future Fertility.

J Pediatr Adolesc Gynecol 2019 Feb 8;32(1):57-63. Epub 2018 Sep 8.

Service de chirurgie pédiatrique, Univ Rennes, CHU Rennes, Inra, Inserm, Institut NUMECAN - UMR_A 1341, UMR_S 1241, Rennes, France. Electronic address:

Study Objective: To develop a predictive score for ovarian malignancy to avoid unnecessary adnexectomy in cases of adnexal mass in pediatric and adolescent girls.

Design: A population-based retrospective study on girls who underwent surgery for an ovarian mass with normal levels of human chorionic gonadotrophin and alpha fetoprotein between 1996 and 2016.

Setting: Rennes University Hospital, Rennes, France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpag.2018.08.009DOI Listing
February 2019
2 Reads

Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US.

Radiology 2018 Dec 11;289(3):740-747. Epub 2018 Sep 11.

From the Department of Biomedical Engineering, Washington University, One Brookings Dr, Mail Box 1097, St Louis, MO 63130 (S.N., A.M., E.A., Q.Z.); Department of Pathology & Immunology (I.S.H.), Department of Obstetrics and Gynecology (I.S.H., M.A.P., D.G.M.), and Mallinckrodt Institute of Radiology (K.R., C.S., Q.Z.), Washington University School of Medicine, St Louis, Mo.

Purpose To assess transvaginal coregistered photoacoustic tomography (PAT) and pulse-echo US for diagnosis of ovarian cancer based on functional parameters provided by PAT. Materials and Methods Between February 2017 and December 2017, 26 ovarian masses from 16 participants were successfully imaged in vivo by multispectral photoacoustic imaging, including nine invasive epithelial ovarian cancers (six serous carcinomas and three endometroid adenocarcinomas), three other tumors (two borderline serous tumors and one sex cord-stromal tumor), and 14 benign and normal (hereafter referred to as benign/normal) ovaries. The relative total hemoglobin concentration (rHbT) and mean oxygen saturation (sO) shown at PAT were used to characterize the ovaries identified at US. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018180666DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283286PMC
December 2018
17 Reads

Factors associated with misdiagnosis of frozen section of mucinous borderline ovarian tumor.

J Int Med Res 2019 Jan 9;47(1):96-104. Epub 2018 Sep 9.

1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China.

Objective: This study was performed to investigate the diagnostic accuracy of frozen section (FS) of mucinous borderline ovarian tumors (mBOTs) and the diagnostic value of various risk factors for misdiagnosis.

Methods: Patients with either an FS or permanent pathologic diagnosis of mBOT were included. Optimum cut-off values for serum tumor markers and maximal tumor diameter were determined, and risk factors for underdiagnosis of mucinous malignant ovarian tumors (mMOTs) were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060518795582DOI Listing
January 2019
21 Reads

Clinicopathological Characteristics of Ovarian Metastasis from Colorectal and Pancreatobiliary Carcinomas Mimicking Primary Ovarian Mucinous Tumor.

Anticancer Res 2018 Sep;38(9):5465-5473

Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Background/aim: A subset of carcinomas metastatic to the ovary can exhibit growth patterns closely resembling ovarian mucinous cystadenoma and borderline tumor. They can be misinterpreted as underlying primary ovarian mucinous tumors and can be erroneously used to suggest that the carcinomatous component arises from mucinous precursor lesions.

Materials And Methods: We investigated the clinicopathological characteristics of 11 cases of metastatic carcinoma that had metastasized from colorectal and pancreatobiliary carcinoma and mimicked primary ovarian mucinous tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12879DOI Listing
September 2018
3 Reads